Legal Campaigns Recruit Wegovy Users as Semaglutide NAION Claims Expand

What Happened

Plaintiff-recruitment campaigns have expanded their focus to semaglutide — the active ingredient in Novo Nordisk's Wegovy weight-management injection and Ozempic diabetes therapy — seeking users who were diagnosed with NAION (non-arteritic anterior ischemic optic neuropathy), a rare condition in which blood flow to the optic nerve is interrupted, causing sudden and usually permanent vision loss in one eye.

The move places the category's most widely prescribed molecule at the center of the GLP-1 vision-loss litigation thread. Earlier claim waves concentrated on Eli Lilly products and on Novo's older liraglutide brands; semaglutide is now the third incretin to draw formal legal attention, and it carries the deepest epidemiological record on the NAION question.

Novo Nordisk continues to dispute causation. The company points to conflicting observational findings and to randomized-trial safety databases that have not reproduced the signal, maintaining that no causal relationship has been established and that the benefit-risk profile of its medicines remains favorable.

Who Is Affected

• Wegovy and Ozempic patients who experienced sudden monocular vision loss — now the target population for legal claim intake.
• Novo Nordisk, which faces allegations of inadequate warning over a rare ocular event on its flagship molecule.
• Prescribers, who are expected to document consent conversations covering sudden-vision-change symptoms for every incretin therapy.
• Gray-market semaglutide sellers, because litigation coverage of the pharmaceutical product extends scrutiny to unregulated copies of the same compound.

Timeline

• 2017-2021 — Semaglutide launches as Ozempic for type 2 diabetes and later as Wegovy for weight management, building the class's largest exposure base.
• 2024 — A population-based study from Danish researchers reports higher NAION incidence among semaglutide users relative to matched controls, drawing worldwide regulatory attention.
• 2025 — Europe's drug-safety committee reviews the signal and concludes a small increase in NAION risk for semaglutide cannot be excluded; rare sudden vision loss is added to European product information.
• 2026 — US vision-loss claims broaden from Lilly products to Novo's; by September, legal intake campaigns are actively recruiting Wegovy users.

What This Means for Researchers

Semaglutide matters most for this signal because its exposure base dwarfs every other incretin's, giving both plaintiffs and epidemiologists more statistical power. Two competing explanations remain unresolved: a genuine vascular effect of the GLP-1 pathway or of rapid metabolic change, versus confounding — NAION shares its principal risk factors, including obesity and cardiovascular disease, with the very population prescribed these drugs.

Legal discovery is likely to surface internal adverse-event reporting, adding public data to a debate that currently rests on observational studies of unequal quality. Until then, the correct reading of the literature is "association under active investigation," not causation.

How to Verify Your Peptides

• Start with the fundamentals in how peptide testing works.
• Follow the HPLC workflow for incretin-class compounds in our semaglutide testing and purity guide.
• Use the third-party peptide testing lab directory to verify any gray-market batch before it enters your workflow.

Safe Alternatives

• Read the full clinical record in our semaglutide profile rather than drawing conclusions from litigation coverage alone.
• Treat every research-grade incretin as requiring batch-specific documentation — see GLP-1 vendor listings that publish certificates of analysis.
• Report unexpected ocular symptoms to a physician immediately; research peptides are not a substitute for medical supervision.

Sources

• Industry reports
• Regulatory announcements